Effects of bimakalim on human cardiac action potentials: Comparison with guinea pig and nicorandil and use-dependent study

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 2, 1999, Pages 255-263

  Rouet, René ^b   Picard, Sandra ^b   Criniti, Anna ^a   Monti, Francesco ^a   Dawodu, Amos Adeyemo ^a   Ruvolo, Giovanni ^a   La Francesca, Saverio ^a   Macrina, Francesco ^a   Tonelli, Euclide ^a   Ducouret, Pierre ^b   Puddu, Paolo Emilio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

Atrial trabeculae; Bimakalim; Human action potential; Nicorandil; Use dependence; Ventricular tissue

Indexed keywords

BIMAKALIM; NICORANDIL;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG SCREENING; FEMALE; GUINEA PIG; HEART ATRIUM; HEART MUSCLE POTENTIAL; HUMAN; MALE; MEMBRANE STEADY POTENTIAL; PRIORITY JOURNAL;

ACTION POTENTIALS; ANIMALS; BENZOPYRANS; CARDIOTONIC AGENTS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUINEA PIGS; HEART; HEART ATRIA; HEART VENTRICLES; HUMANS; MALE; NICORANDIL;

EID: 0032900590     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199902000-00012     Document Type: Article

References (51)

1. van Woerkens LJ, Baas NRA, van der Giessen WJ, Verdouw PD. Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: a comparative study with nicorandil. Cardiovasc Drugs Ther 1992;6:409-17.
2. Senior R, Buchner-Moell D, Raftery E, Lahiri A. Potent hemodynamic effects of bimakalim, a new potassium channel opener, in humans. J Cardiovasc Pharmacol 1993;22:717-21.
3. ATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol 1995;26:145-52.
4. Haverkamp W, Borggrefe M, Breithardt G. Electrophysiologic effects of potassium channel openers. Cardiovasc Drugs Ther 1995;9:195-202.
5. Muller-Ehmsen J, Brixius K, Hoischen S, Schwinger RH. Inotropic and coronary vasodilatatory actions of the K-adenosine triphosphate channel modulator nicorandil in human tissue. J Pharmacol Exp Ther 1996;279:1220-8.
6. Edwards G, Weston AH. Potassium channel openers and vascular smooth muscle relaxation. Pharmacol Ther 1990;48:237-58.
7. Ogbaghebriel A, Shrier A. Differential responsiveness of atrial and ventricular myocytes to potassium channel openers. J Cardiovasc Pharmacol 1995;25:65-74.
8. Gautier P, Bertrand JP, Guiraudou P. Effects of SR 44866, a potassium channel opener, on action potentials of rabbit, guinea pig, and human heart fibers. J Cardiovasc Pharmacol 1991;17:692-700.
9. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The "Sicilian gambit": a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J 1991;12:1112-31.
10. Coraboeuf E, Nargeot J. Electrophysiology of human cardiac cells. Cardiovasc Res 1993;27:1713-25.
11. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:685-90.
12. Cohen I, Datyner N. Repolarizing membrane currents. In: Rosen MR, Janse MJ, Wit AL, ed. Cardiac electrophysiology: a textbook. Prepared in honour of Brian F. Hoffman. Mount Kisco, NY: Futura Publishing, 1990:107-15.
13. Wilde AAM, Janse MJ. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994;28:16-24.
14. Surawicz B. Role of potassium channels in cycle length dependent regulation of action potential duration in mammalian cardiac Purkinje and ventricular muscle fibres. Cardiovasc Res 1992;26:1021-9.
15. Elharrar V, Atarashi H, Surawicz. Cycle length-dependent action potential duration in canine cardiac Purkinje fibers. Am J Physiol 1984;247:H936-45.
16. max by lidocaine but not by disopyramide in guinea-pig papillary muscles. Naunyn Schmiedebergs Arch Pharmacol 1988;337:203-12.
17. Bril A, Man RYK. Effects of the potassium channel activator, BRL 34915, on the action potential characteristics of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1990;253:1090-6.
18. Dawodu AA, Monti F, Iwashiro K, Schiariti M, Chiavarelli R, Puddu PE. The shape of human atrial action potential accounts for different frequency-related changes in vitro. Int J Cardiol 1996;54:237-49.
19. Auchampach JA, Gross GJ. Reduction in myocardial infarct size by the new potassium channel opener bimakalim. J Cardiovasc Pharmacol 1994;23:554-61.
20. Picard S, Rouet R, Monti F, et al. Proarrhythmic effects of DL- and D-sotalol on the "border zone" between normal and ischemic regions of isolated ventricular myocardium and antiarrhythmic effects on reperfusion. J Cardiovasc Pharmacol 1998;31:126-39.
21. Escande D, Loisance D, Planché C, Coraboeuf E. Age-related changes of action potential plateau shape in isolated human atrial fibers. Am J Physiol 1985;249:H843-50.
22. Puddu PE, Picard S, Iwashiro K, et al. Contractile dysfunction following long (60 min) but not repeated shorter (5 min) hypoxia: a stunning model in isolated human atrial muscle. In: Puddu PE, Bing RJ, Campa PP, Poole-Wilson PA, ed. Congestive heart failure: from basic science to therapeutics. Rome: Cardioricerca, 1997:97-119.
23. Puddu PE, Schiariti M, Chiavarelli R, et al. Nicorandil has different electrophysiologic effects in human as compared to guinea-pig atrial cells [Abstract]. Eur Heart J 1992;13(suppl):210.
24. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res 1994;28:303-11.
25. Gelband H, Bush HL, Rosen MR, Myerburg RJ, Hoffman BF. Electrophysiologic properties of isolated preparations of human atrial myocardium. Circ Res 1972;30:293-300.
26. Jakob H, Oelert H, Rupp J, Nawrath H. Functional role of cholinoceptors and purinoceptors in human isolated atrial and ventricular heart muscle. Br J Pharmacol 1989;97:1199-208.
27. Wang Z, Fermini B, Nattel S. Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res 1993;73:276-85.
28. + channel activity and contractile behavior in mammalian ventricle by the potassium channel openers cromakalim and RP 49356. J Pharmacol Exp Ther 1990;255:429-35.
29. + channels of cardiac myocytes. Mol Pharmacol 1989;36:897-902.
30. Tseng GN, Hoffman BF. Actions of pinacidil on membrane currents in canine ventricular myocytes and their modulation by intracellular ATP and cAMP. Pflugers Arch 1990;415:415-24.
31. Furukawa T, Kimura S, Furukawa N, Bassett AL, Myerburg RJ. Role of cardiac ATP-regulated potassium channels in differential responses of endocardial and epicardial cells to ischemia. Circ Res 1991;68:1693-702.
32. ATP channel agonist bimakalim in isolated guinea pig ventricular muscle. Gen Pharmacol 1998;31:125-31.
33. Schiariti M, Puddu PE, Rouet R. Multivariate prediction of spontaneous repetitive responses in ventricular myocardium exposed in vitro to simulated ischemic conditions. Int J Cardiol 1994;45:9-22.
34. Yuan S, Wohlfart B, Olsson SB, Blomström-Lundqvist C. The dispersion of repolarization in patients with ventricular tachycardia, Eur Heart J 1995;16:68-76.
35. Edwards G, Ibbotson T, Weston AH. Levcromakalim may induce a voltage-independent K-current in rat portal veins by modifying the gating properties of the delayed rectifier. Br J Pharmacol 1993;110:1037-48.
36. Grover GJ, D'Alonzo AJ, Hess T, Sleph PG, Darbenzio RB. Glyburide-reversible cardioprotective effects of BMS-180448 is independent of action potential shortening. Cardiovasc Res 1995;30:731-8.
37. + channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995;77:1030-5.
38. Auchampach JA, Cavero I, Gross GJ. Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol 1992;20:765-71.
39. Rohmann S, Weygandt H, Schelling P, et al. Effect of bimakalim (EMD 52692), an opener of ATP sensitive potassium channels, on infarct size, coronary blood flow, regional wall function, and oxygen consumption in swine. Cardiovasc Res 1994;28:858-63.
40. Hearse DJ. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc Res 1995;30:1-17.
41. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769-75.
42. Miyazaki T, Moritani K, Miyoshi S, et al. Nicorandil augments regional ischemia-induced monophasic action potential shortening and potassium accumulation without serious proarrhythmia. J Cardiovasc Pharmacol 1995;26:949-56.
43. + channel activators in cardiac electrophysiology and arrhythmias. Circulation 1992;85:1627-9.
44. Funck Brentano C. Rate-dependence of class III actions in the heart. Fundam Clin Pharmacol 1993;7:51-9.
45. ATP channel opener [Abstract]. Eur Heart J 1995;16(suppl):506.
46. + channels in cardiovascular medicine. Paris: Springer-Verlag, 1993:225-14.
47. + channels in cardiac muscle. Nature 1983;305:147-8.
48. Coetzee WA. ATP-sensitive potassium channels and myocardial ischemia: why do they open? Cardiovasc Drugs Ther 1992;6:201-8.
49. + channels enhances myocardial protection due to cold high potassium cardioplegia: a force-frequency relationship study. J Mol Cell Cardiol 1995;27:1867-81.
50. ATP channels. Arch Mal Coeur 1997;90:556.
51. Robert E, Delye B, Aya B, et al. Comparison and proarrhythmogenic effects of two potassium channel openers, levcromakalim (BRL 38227) and nicorandil (RP 46417): a high-resolution mapping study on rabbit heart. J Cardiovasc Pharmacol 1997;29:109-18.